ArticleMolecules (Basel, Switzerland)2025
Preliminary Study on EGCG-Enhanced Vanadium Toxicity in Cells: Impact on Oxidative Stress.
Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Environmental pollution by heavy metals (HMs) has become a serious threat in recent years due to their potential consequences for human health and life. One such metal is vanadium (V). Despite its numerous benefits-including antibacterial, antifungal, and anticancer properties-V induces cellular damage through oxidative stress. Epigallocatechin gallate (EGCG), a potent antioxidant found in large quantities in green tea, is considered an effective protector against the damaging effects of HMs on cells. The aim of this study was to evaluate the possible effect of EGCG on CHO-K1 cells exposed to V. This is the first experiment of its kind on healthy cells. Cells were treated with V and EGCG for 24 h, either in combination or separately. The doses were selected in a preliminary stage of the experiment (V 50 and 100 µM; EGCG 0.5 and 1 µM). As part of the study, the cell viability, total ROS activity, and mitochondrial membrane potential were assessed. The results showed that at the tested concentrations, EGCG did not reduce the toxic effect of V on cells, but in fact exacerbated its adverse effects on cells. Further studies are needed to understand the exact mechanism of V-EGCG interaction in mammalian cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.